Sugi Predict

Sugi Predict / Targets / TAB1

TAB1

TGF-beta-activated kinase 1 and MAP3K7-binding protein 1 · Q15750 · TAB1 on Sugi Atlas →

9,046 patent compounds predicted against TAB1, 4,317 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL657292 SCHEMBL657292 1.00 20/20
SCHEMBL657304 SCHEMBL657304 1.00 20/20
SCHEMBL657455 SCHEMBL657455 1.00 20/20
SCHEMBL657458 SCHEMBL657458 1.00 20/20
SCHEMBL657459 SCHEMBL657459 1.00 20/20
SCHEMBL657495 SCHEMBL657495 1.00 20/20
SCHEMBL657508 SCHEMBL657508 1.00 20/20
SCHEMBL657706 SCHEMBL657706 1.00 20/20
SCHEMBL658340 SCHEMBL658340 1.00 20/20
SCHEMBL658359 SCHEMBL658359 1.00 20/20
SCHEMBL658373 SCHEMBL658373 1.00 20/20
SCHEMBL658377 SCHEMBL658377 1.00 20/20
SCHEMBL658411 SCHEMBL658411 1.00 20/20
SCHEMBL658578 SCHEMBL658578 1.00 20/20
SCHEMBL658728 SCHEMBL658728 1.00 20/20
SCHEMBL658862 SCHEMBL658862 1.00 20/20
SCHEMBL658995 SCHEMBL658995 1.00 20/20
SCHEMBL658997 SCHEMBL658997 1.00 20/20
SCHEMBL659055 SCHEMBL659055 1.00 20/20
SCHEMBL659097 SCHEMBL659097 1.00 20/20

Clinical trials — most relevant to TAB1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Efficacy and Safety of Deucravacitinib in Takayasu's Arteritis PHASE4NOT_YET_RECRUITING
Diurnal Variation of Plasminogen Activator Inhibitor-1 PHASE4COMPLETED
Clinical Evaluation of the Effect of Metformin in Sepsis PHASE3UNKNOWN
The Use of Inhaled Corticosteroids in the Treatment of Asthma is Children in the Emergency Room PHASE2/PHASE3COMPLETED
Antitumor Activity of Neoadjuvant Chemotherapy with or Without HCW9218 in Metastatic Advanced Stage Ovarian Cancer PHASE2WITHDRAWN
A Study to Evaluate the Safety and Efficacy of Vactosertib and Imatinib in Patients With Advanced Desmoid Tumor PHASE1/PHASE2COMPLETED
TNFSF11 Inhibition and Fertility: a Prospective Study PHASE2COMPLETED
Phase II Study of Vandetanib in Individuals With Kidney Cancer PHASE2COMPLETED
Metformin Repurposing in Oral Submucous Fibrosis: Unveiling In Vitro Signaling Pathways, Progressing to Clinical Trial PHASE1/PHASE2COMPLETED
SB-681323 IV for Subjects at Risk of Acute Lung Injury or ARDS PHASE2COMPLETED
STAR Cape+BKM120 MBC With Brain Met PHASE2COMPLETED
FITMI - First In Treating Male Infertility PHASE2ACTIVE_NOT_RECRUITING
Avelumab in Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma[AVENT STUDY] PHASE2UNKNOWN
Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101 PHASE1WITHDRAWN
First in Human Dose Escalation Study of Vactosertib (TEW-7197) in Subjects With Advanced Stage Solid Tumors PHASE1COMPLETED
Part 2 of Phase 1 Study of GC1008 to Treat Advanced Melanoma (Part 2 Will Only Accept and Treat Patients With Advanced Malignant Melanoma) PHASE1COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA PHASE1COMPLETED
Effect of Aloe Vera Gel and Manuka Honey on Radiation Induced Oral Mucositis nanUNKNOWN
Physiopathology of Pulmonary Arterial Hypertension: Mechanistic Studies nanUNKNOWN
Assessment of the TGF-beta Pathway and Micro-RNA in Pediatric Pulmonary Arterial Hypertension nanUNKNOWN
Investigate eNAMPT in Multiple Myeloma Biology and Establish Its Role in Disease Progression nanCOMPLETED
MicroRNAs and Cytokines in Peri-Implantitis Tissue nanUNKNOWN
Genetic Variation in TRAF3IP2 (rs13190932) nanRECRUITING
Novel Biomarkers in Inflammatory Bowel Disease nanCOMPLETED
Angiotensin II Antagonism of TGF-Beta 1 nanCOMPLETED
Klotho _ LRP-6 _ Gastric Adenocarcinoma nanUNKNOWN
A Retro-/Prospective, Non-interventional, Cohort Study in Adult Patients With Locally Advanced or Metastatic Tumors With a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion, Treated With Larotrectinib nanCOMPLETED
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Role of Novel Biomarkers Associated With In-stent Restenosis After Percutaneous Coronary Intervention nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a TAB1 binder may also engage these)

ProteinNameSimilarity
Q8CF89 — 0.996 Q8CF89 →
Q7XCJ7 — 0.976 Q7XCJ7 →
Q504M2 — 0.975 Q504M2 →
O35099 — 0.971 O35099 →
Q5PNS9 — 0.971 Q5PNS9 →
Q641Y6 — 0.970 Q641Y6 →
Q5Z8P0 — 0.969 Q5Z8P0 →
Q6DDX8 — 0.968 Q6DDX8 →
Q10S32 — 0.968 Q10S32 →
Q9P2J9 — 0.968 Q9P2J9 →
Q7Y138 — 0.968 Q7Y138 →
RAPGEF4 Rap guanine nucleotide exchange factor 4 0.967 landscape →
A7E2V1 — 0.967 A7E2V1 →
Q6ZGY0 — 0.967 Q6ZGY0 →
Q3ZBT2 — 0.967 Q3ZBT2 →
Q7XVF9 — 0.966 Q7XVF9 →
Q0VCN6 — 0.966 Q0VCN6 →
O88484 — 0.966 O88484 →
Q9R1A8 — 0.965 Q9R1A8 →
Q5M8J0 — 0.965 Q5M8J0 →
PLK2 Serine/threonine-protein kinase PLK2 0.965 landscape →
F1R7R1 — 0.964 F1R7R1 →
Q6DJG6 — 0.964 Q6DJG6 →
E7FCN8 — 0.964 E7FCN8 →
Q5MFV5 — 0.964 Q5MFV5 →
Q94H98 — 0.964 Q94H98 →
Q5R4L1 — 0.964 Q5R4L1 →
Q9WV89 — 0.964 Q9WV89 →
P0CI65 — 0.963 P0CI65 →
Q501F9 — 0.963 Q501F9 →